GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
C

Ceribell CBLL · USD

Health Care · US listing · 🇺🇸 United States

Compare

27.60

+3.80%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Ceribell

From its filings with the US Securities and Exchange Commission

SEC filings

Ceribell is based in Sunnyvale, California and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker CBLL. The SEC classifies its business as electromedical & electrotherapeutic apparatus. In the fiscal year to 31 December 2025, it reported revenue of $89.1m and a net loss of $53.4m. At that date it held total assets of $195.8m and shareholders' equity of $155.3m.

In its own words

A seizure is an abnormal burst of uncontrolled electrical activity in the brain which, if left untreated, can result in permanent disability or death. Seizures are often associated with epilepsy, a chronic condition that causes recurring seizures throughout an individual’s life. However, seizures in the acute care setting are also commonly triggered by serious conditions such as brain tumors, traumatic brain injury, stroke, cardiac arrest, and sepsis, among others. In contrast to epileptic seizures which are short in duration and typically involve convulsions, seizures occurring in the acute care setting tend to be longer in duration and are most often non-convulsive, meaning they lack the physical symptoms that are often used to identify seizure activity, which makes empirical diagnosis extremely challenging. This creates a significant unmet need, and it is estimated that up to 92% of all seizures in critical care settings are non-convulsive.

A seizure lasting longer than five minutes is known as status epilepticus, a serious medical emergency that can lead to mortality or severe and permanent brain damage. Awareness of the severity of status epilepticus has significantly increased over the last decade, with a heightened emphasis on prompt diagnosis and treatment, which are the most important factors in appropriately managing the condition and improving patient outcomes. The all-cause mortality rate associated with non-convulsive status epilepticus is approximately 18-30%.

Quoted from its 10-K, filed 24 Feb 2026. Read the filing on SEC.gov ↗

Company facts

Sector
Health Care
Industry
Health Care Equipment & Supplies
Listed since
11 Oct 2024
Employees
327
Head office
360 N. PASTORIA AVENUE, SUNNYVALE, CA, 94085
Incorporated in
DE
Classification
Electromedical & Electrotherapeutic Apparatus
Filer status
Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company

Leadership

Pay as last reported

  • Ms. Rebecca RobertsonIndependent Chairman of the Board$379,367
  • Ms. Xingjuan ChaoPresident, Chief Executive Officer, Director, Co-Founder$1.8m
  • Mr. Scott BlumbergChief Financial Officer$1.0m
  • Dr. Raymond WooChief Technology Officer$703,908
  • Mr. Joseph ManniChief Revenue Officer
  • Dr. Josef ParviziDirector, Co-Founder, since 2015$313,869
  • Ms. Erica RogersDirector
  • Ms. Juliet BakkerIndependent Director$125,319
  • Mr. William BurkeIndependent Director$149,490
  • Mr. Joseph TaylorIndependent Director$247,700
  • Mr. Brian JohnstonInvestor Relations, since 2025

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
36
Environment
39
Social
43
Governance
27
Human rights policy
Yes

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Ceribell System offers point-of-care EEG for rapid diagnosis in acute care settings.
  • Clarity AI algorithm provides real-time EEG interpretation and alerts for status epilepticus.
  • Ceribell employs 327 full-time employees in the Health Care sector.

Weaknesses

  • Ceribell's IPO occurred on 11 October 2024, a recent market entry.
  • Ceribell's headquarters is in Sunnyvale, California, a location with high operational costs.
  • Ceribell's business description mentions only acute care settings without broader applications.

Opportunities

  • Ceribell can expand into global markets beyond the US for neurological diagnosis tools.
  • Ceribell's AI-powered EEG platform may attract partnerships with hospitals in Europe.
  • Ceribell's Clarity AI algorithm could be adapted for other neurological conditions.

Threats

  • Ceribell faces competition from established medical technology firms in the Health Care sector.
  • Ceribell's recent IPO may lead to market volatility affecting its stock performance.
  • Ceribell's focus on acute care settings could limit its market reach compared to broader solutions.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.